Screener / SEC EDGAR /CIK 0001635088 /10-K filed May 20, 2026, compared with May 29, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Roivant Sciences Ltd. ROIV

Compare with peers Embed
FY2026 at a glance

Sales down 71.6%, free cash flow up to -$758.6M

XBRL, from each 10-K
RevenueStatements
$8.3M from $29.1M in FY2025
FY2021FY2026
Net incomeStatements
-$299.8M from -$172.0M in FY2025
FY2021FY2026
Free cash flowStatements
-$758.6M from -$844.0M in FY2025
FY2021FY2026
EPS (diluted)Statements
$-0.54 from $-0.24 in FY2025
FY2021FY2026
Operating marginStatements
-6235.7% from -3453.3% in FY2025
FY2021FY2026

The latest figures

Price and key numbers

From EDGAR
All key numbers (34)
EPS (ttm)
-0.58
Sales (ttm)
41.1M
Net income (ttm)
-344.4M
Sales growth
-71.6%
EPS growth
-
Sales Q/Q
n/m
Free cash flow
-33.3M
Gross margin
-
Oper. margin
n/m
Net margin
-838.2%
FCF margin
-81.2%
R&D / sales
8254.4%
Dividend
-
Debt/Eq
-
Curr. ratio
15.56
Cash
1.6B
Op. cash flow (ttm)
-36.4M
EBITDA
-511.7M
EBITDA margin
n/m
Quick ratio
15.43
FCF after stock pay
-1.1B
Oper. margin low 5y
-6235.7%
Stock pay / sales
4190.9%
Shares out.
724.6M
Shares Y/Y
-4.3%
Book / share
5.55
Cash / share
2.27
Sales / share
0.06
Asset turnover
0.01
Days sales out.
176
Sales 3Y CAGR
-36.0%
Sales 5Y CAGR
-19.1%

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2021 to FY2026

Each fiscal year from its own 10-K · XBRL

Revenue 8.3M -19.1% a year Net income -299.8M
FY2021 revenue 23.8M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001193125-22-183362 FY2021 net income -809.2M · NetIncomeLoss, 0001193125-22-183362 23.8M FY2021 FY2022 revenue 55.3M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001140361-23-031798 FY2022 net income -845.3M · NetIncomeLoss, 0001140361-23-031798 55.3M FY2022 FY2023 revenue 31.5M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001140361-25-020715 FY2023 net income -1.0B · NetIncomeLoss, 0001140361-25-020715 31.5M FY2023 FY2024 revenue 32.7M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001635088-26-000061 FY2024 net income 4.3B · NetIncomeLoss, 0001635088-26-000061 32.7M FY2024 FY2025 revenue 29.1M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001635088-26-000061 FY2025 net income -172.0M · NetIncomeLoss, 0001635088-26-000061 29.1M FY2025 FY2026 revenue 8.3M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001635088-26-000061 FY2026 net income -299.8M · NetIncomeLoss, 0001635088-26-000061 8.3M FY2026

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2021 to FY2026 (5 years).

Growth per share, FY2021 to FY2026

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Book value per share +27.4% a year FY2022 $2.47 to FY2026 $6.52, 4 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Mar 31, 2026 -$0.54$6.52-$1.09
Mar 31, 2025 -$0.24$6.46-$1.16
Mar 31, 2024 $5.23$7.18-$0.92
Mar 31, 2023 -$1.42$1.62-$1.20
Mar 31, 2022 -$1.26$2.47-$1.04
Mar 31, 2021 ---

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2026 · 10-K XBRL, no share price used

Net current asset value, FY2026, in dollars
  • + Current assets $5.2B
  • − All liabilities $416.3M
  • = Net current asset value $4.8B
Per share, year by year
Tangible book value, FY2026, in dollars
  • + Shareholders' equity $4.5B
  • = Tangible book value $4.5B
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

ROIV against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
-71.6%153rd of 155 · median +10.5%
Net margin
-4.1%15.3%
-838.2%153rd of 154 · median 6.8%
Return on equity
-5.2%18.5%
-8.6%110th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
-81.2%136th of 145 · median 10.0%
ROIV and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
ROIV Roivant Sciences Ltd.$41.1M -71.6%--838.2%-8.6%-81.2%-
RXRX Recursion Pharmaceuticals, Inc.$68.2M +26.9%5.0%-697.1%-52.5%-458.0%0.01
OCUL Ocular Therapeutix, Inc$50.4M -18.5%87.3%-648.6%-74.1%-530.0%0.17
IDYA IDEAYA Biosciences, Inc.$36.5M ----38.5%-957.4%-
CRSP CRISPR Therapeutics AG$25.2M -90.6%---27.7%-0.36
CGON CG Oncology, Inc.$6.2M +255%---24.0%-0.00
All 162 companies in the group

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2026 against FY2021 · 10-K XBRL, year-end balances

Return on equity -6.6% FY2021: -45.0% net income ÷ equity
Net margin -3629.2% FY2021: -3400.9% profit per $ of sales: -299.8M ÷ 8.3M
Asset turnover 0.00× FY2021: 0.01× sales per $ of assets: 8.3M ÷ 5.7B
Leverage 1.26× FY2021: 1.44× assets per $ of equity: 5.7B ÷ 4.5B

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin below the peer median
    -838.2% vs 6.8%
  • Return on equity below 15%
    -8.6%
  • A profit in 1 of 6 years
Net margin, FY2021 to FY2026: -3400.9% to -3629.2%

Cash and shareholders

  • Free cash flow positive in 0 of 6 years
    −$758.6M last year
  • Share count up over 4 years
    +3.6%
Free cash flow, FY2021 to FY2026: -557.9M to -758.6M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

ROIV's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 6. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue8.3M
FY2021: 23.8MFY2022: 55.3MFY2023: 31.5MFY2024: 32.7MFY2025: 29.1MFY2026: 8.3M FY2021FY2022FY2023FY2024FY2025FY2026
Net income-299.8M
FY2021: -809.2MFY2022: -845.3MFY2023: -1.0BFY2024: 4.3BFY2025: -172.0MFY2026: -299.8M FY2021FY2022FY2023FY2024FY2025FY2026
Free cash flow-758.6M
FY2021: -557.9MFY2022: -695.2MFY2023: -856.1MFY2024: -766.6MFY2025: -844.0MFY2026: -758.6M FY2021FY2022FY2023FY2024FY2025FY2026
Free cash flow after stock pay-1.1B
FY2021: -642.9MFY2022: -1.3BFY2023: -1.1BFY2024: -966.3MFY2025: -1.1BFY2026: -1.1B FY2021FY2022FY2023FY2024FY2025FY2026
EPS (diluted)-0.54
FY2021: -1.28FY2022: -1.26FY2023: -1.42FY2024: 5.23FY2025: -0.24FY2026: -0.54 FY2021FY2022FY2023FY2024FY2025FY2026
Diluted shares693.9M
FY2021: -FY2022: 669.8MFY2023: 712.8MFY2024: 831.0MFY2025: 725.4MFY2026: 693.9M FY2021FY2022FY2023FY2024FY2025FY2026

Income statement

From EDGAR
FY2021FY2022FY2023FY2024FY2025FY2026
Revenue23.8M55.3M31.5M32.7M29.1M8.3M
R&D236.6M483.0M454.1M439.9M550.4M681.8M
SG&A259.9M775.0M600.5M687.4M591.4M610.5M
Operating income-1.1B-1.4B-906.8M4.5B-1.0B-515.1M
Interest expense2.8M7.0M28.0M34.8M6.0M0
Pretax income-898.5M-923.7M-885.0M4.6B-681.6M-264.6M
Income tax1.7M369K4.1M21.5M48.2M133.3M
Net income-809.2M-845.3M-1.0B4.3B-172.0M-299.8M
EPS (diluted)-1.28-1.26-1.425.23-0.24-0.54
Diluted shares-669.8M712.8M831.0M725.4M693.9M
Depreciation & amortization-5.9M18.9M22.0M14.1M3.3M
EBITDA--1.3B-887.9M4.5B-989.2M-511.7M
Operating margin-4500.5%-2444.8%-2875.9%13746.9%-3453.3%-6235.7%
Net margin-3400.9%-1528.9%-3200.2%13294.2%-592.0%-3629.2%
Revenue growth-+132%-43.0%+3.8%-11.2%-71.6%
EPS growth----to a loss-

Balance sheet

From EDGAR
FY2021FY2022FY2023FY2024FY2025FY2026
Cash2.1B2.1B1.7B6.5B2.7B1.4B
Short-term investments---02.2B2.9B
Receivables11.2M3.9M30.4M4.0M--
Inventory-02.8M35.3M--
Current assets2.2B2.1B1.8B6.7B5.0B5.2B
Property & equipment14.7M25.9M39.1M15.3M12.1M12.0M
Other intangible assets-0144.9M137.8M--
Total assets2.6B2.6B2.4B7.2B5.4B5.7B
Accounts payable20.6M34.6M37.8M14.0M23.7M18.0M
Current liabilities219.0M184.4M272.4M266.8M149.4M281.2M
Total debt170.3M210.0M375.5M430.6M--
Total liabilities527.7M523.7M782.0M774.0M249.7M416.3M
Shareholders' equity1.8B1.7B1.2B6.0B4.7B4.5B
Retained earnings-1.9B-2.8B-3.8B576.2M116.1M-501.8M

Cash flow

From EDGAR
FY2021FY2022FY2023FY2024FY2025FY2026
Operating cash flow-552.1M-677.7M-843.4M-765.3M-839.5M-750.3M
Capital spending5.8M17.4M12.7M1.4M4.6M8.2M
Free cash flow-557.9M-695.2M-856.1M-766.6M-844.0M-758.6M
Stock-based pay (added back)85.0M565.0M217.8M199.6M289.0M346.2M
Free cash flow after stock pay-642.9M-1.3B-1.1B-966.3M-1.1B-1.1B
Buybacks--001.3B-
Investing cash flow-31.7M303.3M-44.3M5.2B-1.8B-682.3M
Financing cash flow456.3M306.8M499.5M419.4M-1.2B134.2M

Stock-based pay and leases

From EDGAR
FY2021FY2022FY2023FY2024FY2025FY2026
Stock-based pay (expense)85.0M565.0M217.8M199.6M289.0M346.2M
Stock-based pay / revenue357.0%1021.9%690.7%610.2%994.8%4190.9%
Operating lease cost11.9M13.6M10.9M10.6M11.6M16.0M
Operating lease cash paid8.8M14.4M11.7M11.6M10.3M10.4M
Finance lease principal paid-0692K1.5M774K0
Right-of-use assets62.3M61.0M53.3M44.0M89.0M80.4M
Operating lease liabilities74.7M73.9M65.2M57.2M100.2M107.4M
Finance lease liabilities--5.7M---

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ROIV/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.